ALKS vs AMGN · P/E 14, rev $1.56B vs P/E 24, rev $36.75B
Alkermes Plc (ALKS) versus Amgen Inc (AMGN) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Not investment advice. Open the ALKS and AMGN stock pages for the full models.
Not investment advice.